Clinical Trials Browser

Neoplasms × Cisplatin × Tumor-Agnostic × Clear all

NCT05382559 2026-03-02

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis, Neoplasms

NCT05516914 2025-11-28

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Phase 1 Completed

Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Neoplasms

NCT01369641 2025-05-16

The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

Phase NA Terminated

1 enrolled 6 charts

Neoplasms

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Phase 1 Completed

829 enrolled 100 charts

Neoplasms

NCT06696742 2024-11-20

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

Phase 2 Recruiting

Neoplasms

NCT05241132 2022-02-15

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Phase 2 Unknown

Neoplasms

NCT02723864 2022-02-08

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Phase 1 Completed

53 enrolled 20 charts

Neoplasms

NCT04217512 2020-01-03

Pantoprazole in Cisplatin Nephrotoxicity

Phase 3 Recruiting

Neoplasms

NCT01031420 2019-09-17

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Phase 2 Completed

54 enrolled 7 charts

Neoplasms

NCT01868022 2019-08-19

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Phase 1 Completed

65 enrolled 32 charts

Neoplasms

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1/2 Terminated

15 enrolled 11 charts

Neoplasms

NCT00678132 2018-07-05

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

Phase 1 Completed

Neoplasms

NCT01285037 2018-02-20

A Study of LY2801653 in Advanced Cancer

Phase 1 Completed

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

Neoplasms

NCT01460537 2017-10-04

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT00226239 2017-07-11

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Phase 2 Completed

39 enrolled 10 charts

Neoplasms

NCT01355302 2017-05-15

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Phase 1/2 Terminated

7 enrolled 8 charts

Neoplasms

NCT00551512 2017-03-14

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

Phase 1 Completed

Neoplasms

NCT02723838 2017-03-07

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Phase 1 Withdrawn

Neoplasms

NCT01980667 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT02250872 2016-04-20

Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury

Phase 2/3 Unknown

Neoplasms

NCT01909856 2015-12-04

The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy

Phase 2 Completed

Neoplasms

NCT01096199 2014-01-22

A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)

Phase 1 Terminated

Neoplasms

NCT00454649 2012-04-04

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Phase 1 Completed

102 enrolled 48 charts

Neoplasms

NCT01021150 2011-06-13

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00249977 2010-01-07

Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan

Phase 1 Completed

Neoplasms